在基化疗后感应神经听力损失的早期标志物
Heleen Van Der Biest1,2, Sarineh Keshishzadeh2, Hannah Keppler3,4
1Department of Head and Skin, Ghent University, Ghent, Belgium.
Ear and hearing
|September 1, 2025
概括
化疗可能会导致听力损失. 在听力测量变化之前,封面后反应 (EFR) 显示早期损伤,这表明EFR是监测耳毒性的关键标志物.
科学领域:
- 听力学
- 神经科学
- 癌症学
背景情况:
- 基于的化疗 (cisplatin,carboplatin) 可以引起耳毒性,损害内耳结构.
- 目前通过纯色音量计进行的监测不足以检测早期的外皮毛细胞损伤.
- 衍生物可能通过损伤听觉神经纤维引起耳突触 (CS).
研究的目的:
- 评估衍生品对听觉结果的影响.
- 评估非侵入性脑电图测量,特别是包膜追踪反应 (EFR) 的有用性,以检测耳突触 (CS).
主要方法:
- 接受西斯普拉丁或卡博普拉丁治疗的37名患者接受了基线和后续听力评估 (治疗后2-10个月).
- 测试包括常规/扩展高频音频测量,DPOAEs,ABR和EFR.
- 配对的t测试和回归分析评估了听力和EFR相对于化疗剂量和基线状态的变化.
主要成果:
- 在化疗后的更高频率观察到显著的听觉值变化.
- 累积化疗剂量与听力值恶化相关.
- 在治疗后发现EFR大小显著下降,特别是在西斯普拉丁组,主观投诉或显著的听力学变化之前.
结论:
- 耳毒性监测应包括扩展高频率和客观措施,如EFR.
- EFR大小作为一种有价值的非侵入性标记,用于检测基化疗诱导的CS.
- EFR的下降表明早期的耳毒性,支持将其纳入监测协议以加强早期检测.
相关概念视频
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...